Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway

Cancer

Volumn 116, Issue 15, 2010, Pages 3603-3613

  Ai, Zhihong ^a   Wang, Juan ^a   Wang, Yudong ^a   Lu, Lihua ^a   Tong, Jianqian ^a   Teng, Yincheng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Endometrial carcinoma; Epidermal growth factor receptor; Hormone therapy; Progesterone receptor; Resistance

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MESSENGER RNA; PROGESTERONE RECEPTOR B;

ADULT; AGED; ARTICLE; CARCINOMA CELL; CELL CULTURE; DRUG SENSITIVITY; ENDOMETRIUM CARCINOMA; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MEDROXYPROGESTERONE; PROGESTERONE; PROGESTINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFECTION; UP-REGULATION;

EID: 77955401462     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25220     Document Type: Article

References (32)

1. Doll A, Abal M, Rigau M, et al. Novel molecular profiles of endometrial cancer - new light through old windows. J Steroid Biochem Mol Biol. 2008;108:221-229.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:28-29.
3. Lentz SS. Endocrine therapy of endometrial cancer. Cancer Treat Res. 1998;94:89-106.
4. Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril. 2003;80:1315-1324. (Pubitemid 37532439)
5. Niwa K, Tagami K, Lian Z, Onogi K, Mori H, Tamaya T. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG. 2005;112:317-320.
6. Yang YC, Wu CC, Chen CP, Chang CL, Wang KL. Re-evaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer. Gynecol Oncol. 2005;99:287-293.
7. Vecek N, Nola M, Marusic M, et al. Prognostic value of steroid hormone receptors concentration in patients with endometrial carcinoma. Acta Obstet Gynecol Scand. 1994; 73: 730-733. (Pubitemid 24342037)
8. Dai D, Kumar NS, Wolf DM, Leslie KK. Molecular tools reestablish progestin control of endometrial cancer cell proliferation. Am J Obstet Gynecol. 2001;184:790-797.
9. Sakaguchi H, Fujimoto J, Hong BL, et al. Drastic decrease of progesterone receptor form B but not A mRNA reflects poor patient prognosis in endometrial cancers. Gynecol Oncol. 2004;93:394-399.
10. Khalifa MA, Abdoh AA, Manuel RS, et al. Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer. 1994;73:370-376. (Pubitemid 24030616)
11. Wang DP, Konishi I, Koshiyama M, et al. Expression of cerbB-2 protein and epidermal growth factor receptor in endometrial carcinomas. Cancer. 1993;72:2628-2637.
12. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37:s9-s15.
13. Nicholson RI, Staka C, Boyns F, Hutcheson IR, Gee JM. Growth factor driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr Relat Cancer. 2004;11:623-641.
14. Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer. 2005;12:S29-S36.
15. Zhao SJ, Chen XJ, Lu X, et al. Epidermal growth factor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma. Gynecol Oncol. 2007; 105:45-54. (Pubitemid 46441469)
16. Pecorelli S, Benedet JL, Creasman WT, Shepherd JH. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynecol Obstet. 1999;64:5-10.
17. Ai ZH, Yin LH, Zhou XR, et al. Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer. 2006;107:746-756.
18. Zhou YH, Tan F, Hess KR, et al. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res. 2003;9:3369-3375.
19. Goldman S, Shalev E. Difference in progesterone-receptor isoforms ratio between early and late first-trimester human trophoblast is associated with differential cell invasion and matrix metalloproteinase 2 expression. Biol Reprod. 2006;74:13-22. (Pubitemid 43068785)
20. Miyamoto T, Watanabe J, Hata H, et al. Significance of progesterone receptor-A and -B expression in endometrial adenocarcinoma. J Steroid Biochem Mol Biol. 2004;92:111-118.
21. Dai D, Wolf DM, Litman ES, White MJ, Leslie KK. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res. 2002;62:881-886.
22. Hanekamp EE, Gielen SC, Smid-Koopman E, et al. Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Clin Cancer. 2003;9:4190-4199. (Pubitemid 37204039)
23. Lelle RJ, Talavera F, Gretz H, et al. Epidermal growth factor receptor expression in 3 different human endometrial caner cell lines. Cancer. 1993;72:519-525. (Pubitemid 23193461)
24. Magdnlena B, Andrzeg S, Tomasz R, et al. Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium. Oncol Rep. 2007;18:261-265.
25. Schimp VL, Ali-Fehmi R, Solomon LA, et al. The racial disparity in outcomes in endometrial cancer: could this be explained on a molecular level? Gynecol Oncol. 2006;102:440-446.
26. Leslie KK, Kumar NS, Richer J, et al. Differential expression of the A and B isoforms of progesterone receptor in human endometrial cancer cells. Only progesterone receptor B is induced by estrogen and associated with strong transcriptional activation. Ann NY Acad Sci. 1997;828:17-26.
27. Kumar NS, Richer J, Owen G, et al. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action. Cancer Res. 1998;58:1860-1865.
28. Hanekamp EE, Kuhne LM, Grootegoed JA, et al. Progesterone receptor A and B expression and progestagen treatment in growth and spread of endometrial cancer cells in nude mice. Endocr Relat Cancer. 2004;11:831-841.
29. Murphy LC, Dotzlaw H, Wong MS, Miller T, Murphy LJ. Mechanisms involved in the evolution of progestin resistance in human breast cancer cells. Cancer Res. 1991;51:2051-2057.
30. Boonyaratanakornkit V, McGowan E, Sherman L, et al. The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol. 2007;21:359-375.
31. Shushan A, Rojansky N, Laufer N, et al. The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth. Human Reprod. 2004;19:1957-1967. (Pubitemid 39236459)
32. Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol. 2006;58:242-256.